Clinical Trials

34 enrolled

Small Cell Lung Carcinoma

NCT04877821 2026-04-02

NeoSACT

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05001971 2026-01-15

Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy

65 enrolled

Small Cell Lung Carcinoma

NCT04574284 2025-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

170 enrolled

Gynecologic

Advanced Endometrial Cancer

NCT04996758 2024-12-12

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

40 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT04691388 2024-12-05

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

29 enrolled

NSCLC

NCT04860700 2024-06-12

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

27 enrolled

CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05493995 2024-05-09

PAAG

66 enrolled

Pancreatic Neoplasms

NCT04271813 2024-04-23

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

30 enrolled

Colorectal Neoplasms

NCT03906058 2023-10-25

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

39 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

21 enrolled

Lung Neoplasms

NCT06015035 2023-08-29

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

17 enrolled

Esophageal Neoplasms

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

42 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03743129 2023-06-12

ALTER-L029

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05130515 2023-01-31

CC-ANNIE

6 enrolled

Gynecologic

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

80 enrolled

Breast

Breast Neoplasms

NCT03736837 2021-03-15

ALTER-L004

60 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

26 enrolled

Breast

Breast Neoplasms

NCT04216082 2020-01-02

A Study of Anlotinib in Subjects With Advanced Malignancy

93 enrolled

Advanced Malignancy

NCT02649361 2019-06-05

Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

164 enrolled

Esophageal Squamous Cell Carcinoma

NCT01878448 2019-05-22

ALTN/STS

166 enrolled

Tumor-Agnostic

Neoplasms

NCT01874873 2019-05-21

ALTN/MTC

58 enrolled

Tumor-Agnostic

Neoplasms

NCT03059797 2019-05-16

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

120 enrolled

Small Cell Lung Carcinoma

NCT01924195 2015-10-28

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

117 enrolled